Pictet Asset Management
SNDX icon

Pictet Asset Management’s Syndax Pharmaceuticals SNDX Stock Holding History

Pictet Asset Management’s Portfolio SNDX Stock Details SNDX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$4.53M Buy
207,936
+195,580
+1,583% +$4.07M ﹤0.01% 814
2026
Q1 		$289K Hold
12,356
– – ﹤0.01% 1734
2025
Q4 		$260K Hold
12,356
– – ﹤0.01% 1784
2025
Q3 		$190K Hold
12,356
– – ﹤0.01% 1893
2025
Q2 		$116K Buy
+12,356
New +$136K ﹤0.01% 1918

Other funds holding SNDX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
KCM
Kynam Capital Management Princeton, New Jersey $1.81B AUM 192.15% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
DM
Deerfield Management New York $9.59B AUM 113.36% 1-Year Est. Return
EP
Eversept Partners New York $1.93B AUM 160.8% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
HRCM
Hood River Capital Management Palm Beach Gardens, Florida $13.8B AUM 163.97% 1-Year Est. Return

Pictet Asset Management's SNDX Position: Q2 2026 in Review

Pictet Asset Management increased its Syndax Pharmaceuticals (SNDX) stake by 1,583% in Q2 2026, buying an estimated $4.07M and bringing the position to 207,936 shares worth $4.53M. The position accounts for ﹤0.01% of the portfolio, ranked #814.

Pictet Asset Management first reported a position in SNDX in Q2 2025 and has held it in 5 quarters since. 242 funds tracked by Wall St. Rank hold SNDX as of Q2 2026.

  • Pictet Asset Management held 207,936 shares of Syndax Pharmaceuticals worth $4.53M as of Q2 2026.
  • Pictet Asset Management bought 195,580 Syndax Pharmaceuticals shares in Q2 2026, an estimated $4.07M.
  • Syndax Pharmaceuticals made up ﹤0.01% of Pictet Asset Management's portfolio in Q2 2026, its #814 holding.
  • Pictet Asset Management first reported a position in Syndax Pharmaceuticals in Q2 2025 and has held it in 5 quarters since.
  • 242 funds tracked by Wall St. Rank held Syndax Pharmaceuticals as of Q2 2026.

Based on Pictet Asset Management's 13F filing for Q2 2026, filed 30 Jul 2026.